Charles River Laboratories Cash on Hand 2010-2024 | CRL

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Charles River Laboratories cash on hand for 2023 was $0.277B, a 18.32% increase from 2022.
Charles River Laboratories cash on hand for 2022 was $0.234B, a 3.03% decline from 2021.
Charles River Laboratories cash on hand for 2021 was $0.241B, a 5.6% increase from 2020.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Charles River Laboratories cash on hand for 2023 was $0.277B, a 18.32% increase from 2022.
Charles River Laboratories cash on hand for 2022 was $0.234B, a 3.03% decline from 2021.
Charles River Laboratories cash on hand for 2021 was $0.241B, a 5.6% increase from 2020.

Related Stocks
Company Name	Market Cap
Elevance Health (ELV)	$91.4B
Cencora (COR)	$47.5B
DiDi Global (DIDIY)	$23.3B
Natera (NTRA)	$21.4B
ICON (ICLR)	$16.1B
Viatris (VTRS)	$15.6B
Avantor (AVTR)	$13.4B
Revvity (RVTY)	$13.4B
CochLear (CHEOY)	$12.8B
BioMerieux (BMXMF)	$12.7B
Solventum (SOLV)	$11.6B
Medpace Holdings (MEDP)	$9.8B
Doximity (DOCS)	$9.6B
HealthEquity (HQY)	$9B
Sonic Healthcare (SKHHY)	$8.8B
Bausch + Lomb (BLCO)	$6.9B
Life Times (LTH)	$5.1B
Sotera Health (SHC)	$3.9B
Organon (OGN)	$3.8B
BrightSpring Health Services (BTSG)	$3.2B
Surgery Partners (SGRY)	$2.9B
PACS (PACS)	$2.6B
Concentras Parent (CON)	$2.6B
Ardent Health Partners (ARDT)	$2.4B
Premier (PINC)	$2.1B
Alignment Healthcare (ALHC)	$2.1B
Ryman Healthcare (RYHTY)	$2B
GeneDx Holdings (WGS)	$2B
GoodRx Holdings (GDRX)	$1.6B
Teladoc Health (TDOC)	$1.5B